Corrigendum | Published:

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia volume 31, page 775 (2017) | Download Citation

Correction to: Leukemia (2016) 30, 1701–1707; doi:10.1038/leu.2016.148

Following the publication of this article the authors noted that the IPSS risk assignment was incorrectly listed in the second paragraph of the Results section. The correct proportions of patients with intermediate-2-risk or high-risk MF should be 40 and 60%, respectively, not 60 and 40% as listed in the original.

The authors wish to apologize for any inconvenience caused.

About this article

Publication history




  1. Search for C N Harrison in:

  2. Search for A M Vannucchi in:

  3. Search for J-J Kiladjian in:

  4. Search for H K Al-Ali in:

  5. Search for H Gisslinger in:

  6. Search for L Knoops in:

  7. Search for F Cervantes in:

  8. Search for M M Jones in:

  9. Search for K Sun in:

  10. Search for M McQuitty in:

  11. Search for V Stalbovskaya in:

  12. Search for P Gopalakrishna in:

  13. Search for T Barbui in:

Further reading